PMID- 22244520
OWN - NLM
STAT- MEDLINE
DCOM- 20120719
LR  - 20170112
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 30
IP  - 1
DP  - 2012 Jan-Feb
TI  - Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on 
      monocytes/neutrophils, and is regulated by TNF antagonist in patients with 
      rheumatoid arthritis.
PG  - 99-102
AB  - OBJECTIVES: Human six-transmembrane epithelial antigen of prostate 4 (STEAP4) is 
      one of the STEAP family as a homologue of mouse tumour necrosis factor-alpha-induced 
      adipose-related protein (TIARP). Recently, we reported that the TIARP gene 
      expression was remarkably increased in spleen and joints of glucose-6-phosphate 
      isomerise (GPI)-induced arthritis model, suggesting pivotal association to 
      arthritis. The aim of the present study was to assess the expression, 
      localisation and function of STEAP4 in peripheral blood of patients with 
      rheumatoid arthritis (RA). METHODS: Peripheral blood was obtained from seven 
      patients with RA, the surface expression of STEAP4 was detected by flow 
      cytometry. The number of neutrophils was compared with the expression of STEAP4 
      mRNA derived from peripheral blood of patients with RA. Neutrophils were 
      introduced by HL60 with retinoic acid, and were transfected with GFP-STEAP4 
      plasmid DNA, then the migration of neutrophil-like HL60 was determined by 
      transwell assay. In addition, the fluctuation of STEAP4 mRNA was analysed before 
      and after treatment with infliximab in 40 patients with RA. RESULTS: STEAP4 was 
      expressed on monocytes and neutrophils in peripheral blood in RA. The number of 
      neutrophils and expression of STEAP4 mRNA was positively correlated. Migration of 
      neutrophil-like HL60 was down-regulated by over-expression of STEAP4. Expression 
      of STEAP4 Mrna was significantly decreased after infliximab treatment in patients 
      with RA, especially in good responders. CONCLUSIONS: STEAP4 is expressed on 
      monocytes and neutrophils in peripheral blood, regulates cell migration, is 
      down-regulated by TNF antagonist, and might be a possible predictor of response 
      to TNF antagonist.
FAU - Tanaka, Y
AU  - Tanaka Y
AD  - Division of Clinical Immunology, Doctoral Programme in Clinical Science, Graduate 
      School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan.
FAU - Matsumoto, I
AU  - Matsumoto I
FAU - Iwanami, K
AU  - Iwanami K
FAU - Inoue, A
AU  - Inoue A
FAU - Umeda, N
AU  - Umeda N
FAU - Tanaka, Y
AU  - Tanaka Y
FAU - Sugihara, M
AU  - Sugihara M
FAU - Hayashi, T
AU  - Hayashi T
FAU - Ito, S
AU  - Ito S
FAU - Sumida, T
AU  - Sumida T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120306
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Membrane Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - EC 1.- (Oxidoreductases)
RN  - EC 1.16.1.- (STEAP4 protein, human)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Antirheumatic Agents/pharmacology/therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy/*metabolism
MH  - Cell Movement/physiology
MH  - Down-Regulation/drug effects
MH  - Humans
MH  - Infliximab
MH  - Membrane Proteins/*metabolism
MH  - Monocytes/drug effects/*metabolism
MH  - Neutrophils/drug effects/*metabolism
MH  - Oxidoreductases/*metabolism
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2012/01/17 06:00
MHDA- 2012/07/20 06:00
CRDT- 2012/01/17 06:00
PHST- 2011/01/24 00:00 [received]
PHST- 2011/09/06 00:00 [accepted]
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2012/07/20 06:00 [medline]
AID - 4706 [pii]
PST - ppublish
SO  - Clin Exp Rheumatol. 2012 Jan-Feb;30(1):99-102. Epub 2012 Mar 6.